Avazo-Healthcare warned by the FDA about its coronavirus disease 2019 (COVID-19) testing kits; Pfizer, BioNTech get first COVID-19 vaccine approval; risk for Guillan-Barré syndrome from flu vaccine deemed insignificant.
In a warning letter, the FDA has instructed Avazo-Healthcare to take immediate action and cease the sale of 2 coronavirus disease 2019 (COVID-19) antigen test kits and several serology test kits, citing they do not have market approval or authorization for direct-to-consumer sales. The FDA is also accusing the limited liability corporation of failing to notify the federal agency that it would be introducing the tests for distribution. The letter also included a warning to rectify potential false claims that the company’s cannabidiol products can prevent, mitigate, and treat COVID-19.
An emergency authorization was handed down from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for Pfizer and BioNTech’s COVID-19 vaccine, reported The New York Times. A total of 800,000 doses could be ready for distribution next week, and 40 million doses have been pre-ordered. The fast-tracked approval came about due to Britain being allowed to circumnavigate the European Union’s typical regulatory process in public health emergencies. The FDA is set to meet on December 10 and 17 to discuss approving the Pfizer/BioNTech and Moderna vaccines for use in the United States.
According to study results published in The Journal of Infectious Diseases, the risk for this rare disease, in which the immune system attacks nerves, is statistically insignificant in light of the benefits the flu vaccine bestows on older Americans. Just 1 case of Guillain-Barré was seen in the risk (days 8-21 and 1-42 post vaccination) and control (days 43-84 post vaccination) windows of the study, which saw close to 22 million patients receive the high-dose influenza vaccine during the 2018-2019 flu season.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More